Sonnet BioTherapeutics (NASDAQ:SONN – Get Rating) had its price target increased by equities research analysts at Chardan Capital to $22.00 in a report released on Thursday, September 22nd, The Fly reports. The firm currently has a “buy” rating on the stock.
Sonnet BioTherapeutics Trading Up 2.8 %
Shares of Sonnet BioTherapeutics stock traded up $0.04 on Thursday, hitting $1.47. 138,814 shares of the company’s stock were exchanged, compared to its average volume of 320,239. The company has a 50-day simple moving average of $3.14 and a 200-day simple moving average of $3.92. Sonnet BioTherapeutics has a 1 year low of $1.23 and a 1 year high of $10.22.
Sonnet BioTherapeutics (NASDAQ:SONN – Get Rating) last released its earnings results on Monday, August 15th. The company reported ($1.82) earnings per share for the quarter. Sonnet BioTherapeutics had a negative net margin of 3,792.35% and a negative return on equity of 243.91%. The firm had revenue of $0.06 million for the quarter. As a group, equities analysts anticipate that Sonnet BioTherapeutics will post -6.68 earnings per share for the current year.
Institutional Inflows and Outflows
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
- Get a free copy of the StockNews.com research report on Sonnet BioTherapeutics (SONN)
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.